MedPath

Non-interventional Study to Evaluate the Change in Symptoms Scores and Treatment Response After 4 Weeks of Proton-Pump Inhibitors (PPI) Treatment

Completed
Conditions
Gastroesophageal Reflux
Registration Number
NCT01103804
Lead Sponsor
AstraZeneca
Brief Summary

The primary objective of the study is to describe the change in GerdQ sum scores, after a 4-week period of systematic treatment with PPIs(using GerdQ questionnaire). The secondary objectives are: to measure the response at the current treatment after a 4-week period of systematic treatment and to identify the percentage of patients which require alterations of their treatment (GerdQ questionnaire)

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
952
Inclusion Criteria
  • Provision of informed consent
  • Patients known or newly diagnosed with GERD or patients with typical symptoms of GERD- heartburn, regurgitation (in the last case, GerdQ sum score should be ≥8, in the absence of PPI treatment)
Exclusion Criteria
  • Any symptoms at visit 1 suggesting a need for further investigation, judged by the Investigator (alarm symptoms).The alarm symptoms suggesting complicated disease are: dysphagia, odynophagia, bleeding, weight loss without intention or anemia.
  • Previous participation in the present study

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
describe the change in GerdQ sum scores, after a 4-week period of systematic treatment with PPIs(GerdQ)4 weeks(at V1 and V2)
Secondary Outcome Measures
NameTimeMethod
measure the response at the current treatment after a 4-week period of systematic treatment with PPIs(GerdQ)4 weeks(at V1 and V2)
identify the percentage of patients which require alterations of their treatment after a 4-week period of systematic treatment with PPIs(GerdQ)4 weeks(at V1 and V2)

Trial Locations

Locations (1)

Research Site

🇷🇴

Vanatori(GL), Romania

© Copyright 2025. All Rights Reserved by MedPath